Dr. Karsh Discusses Treatment Sequencing in mCRPC

Lawrence Karsh, MD, director of the Clinical Research Department, at The Urology Center of Colorado, discusses strategies for sequencing the wide array of new agents available to treat men with castration-resistant prostate cancer.

Given the overall lack of data on sequencing, Karsh recommends utilizing practical considerations to determine how to best treat patients. These parameters include patient preference, comorbidities, and financial considerations. Furthermore, he notes, with the overall lack of available guidelines and biomarkers, most patients will likely receive several of the approved therapies.